|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
|
26980062 |
2016 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
On July 13, 2015, the FDA approved gefitinib (Iressa; AstraZeneca UK Limited) for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by an FDA-approved test.
|
26980062 |
2016 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
U.S. Food and Drug Administration approval summary: Erlotinib for the first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 (L858R) substitution mutations.
|
24868098 |
2014 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
It is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) carrying EGFR exon 19 deletions or exon 21 (L858R) mutations.
|
24844234 |
2014 |
|
rs1057519847
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oral afatinib (Gilotrif™) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.
|
23982599 |
2013 |
|
rs1057519848
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oral afatinib (Gilotrif™) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.
|
23982599 |
2013 |
|
rs121434568
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Oral afatinib (Gilotrif™) has been approved in the US for the first-line treatment of patients with metastatic non-small-cell lung cancer (NSCLC) who have tumours with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations as detected by a US FDA-approved test.
|
23982599 |
2013 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
We detected high copy numbers of epidermal growth factor receptor mutations (L858R and T790M) in the cfDNA samples from stage IV NSCLC patients who underwent stereotactic body radiation therapy to treat brain metastasis related to tyrosine kinase inhibitor (TKI) treatment failure.
|
29721209 |
2018 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
|
29242281 |
2018 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Third-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) such as osimertinib are the last line of targeted treatment of metastatic non-small-cell lung cancer (NSCLC) EGFR-mutant harboring T790M.
|
28961841 |
2017 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
The European Commision (EC) recently approved osimertinib for the treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring EGFR T790M mutations.
|
28884371 |
2017 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Epidermal growth factor receptor T790M mutation-positive metastatic non-small-cell lung cancer: focus on osimertinib (AZD9291).
|
28367058 |
2017 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience.
|
27784815 |
2016 |
|
rs121434569
|
|
|
0.070 |
GeneticVariation |
BEFREE |
There is limited information available concerning the prevalence of primary T790M mutations in patients with metastatic NSCLC tumors before treatment with EGFR-TKIs.
|
24789720 |
2014 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and was approved by the European Medicines Agency and United States Food and Drug Administration for patients with stage IV NSCLC harboring BRAF V600E mutation.
|
29595366 |
2019 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
BRAF-MEK combination therapy (dabrafenib plus trametinib) demonstrated tolerability and efficacy in a recent phase II clinical trial and was approved by the European Medicines Agency and United States Food and Drug Administration for patients with stage IV NSCLC harboring BRAF V600E mutation.
|
29595366 |
2019 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC).
|
29949047 |
2018 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
|
30121602 |
2018 |
|
rs113488022
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Outcomes in patients with stage iv nsclc harbouring <i>BRAF</i> V600E mutations (<i>n</i> = 32) did not differ significantly from those of patients with other <i>BRAF</i> mutations.
|
30464690 |
2018 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Due to the rarity of BRAF V600E mutation, no randomized study has compared the combination targeted therapy dabrafenib + trametinib with other second-line treatments for advanced or metastatic non-small-cell lung cancer (NSCLC).
|
29949047 |
2018 |
|
rs121913377
|
|
|
0.050 |
GeneticVariation |
BEFREE |
Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data.
|
30121602 |
2018 |